MarketsandMarkets BioProduction Manufacturing Crystal Ball Event
High growth markets which contribute to 20% of your revenues today will contribute 80% in the next 5 years. Identify these new revenue sources at MarketsandMarkets’ s Crystal Ball event
The end product sales in bioproduction market are expected to grow at over `15% to be a $305 Bn market in 2025. Numerous engines are expected to fuel its growth – Cell Therapy, Gene Therapy, Monoclonal Antibodies, Vaccines, biosimilars and bio betters, plasma therapy as well as others.
A host of attractive, high growth opportunities such as single use systems, Lab Scale and CGMP manufacturing and R&D, Crispr and other Gene editing tools and technologies, Novel downstream bioprocessing methods etc. could be pursued. Participants such as CROs, CMOs, Bioprocess solutions manufacturers, Biobanks, automation technology providers etc. can benefit from this unprecedented growth over the next 5 years.
This Crystal Ball event focuses on learning more about the most promising opportunities in the Bioproduction ecosystem, as seen through the lens of eminent CXOs in this space
Continuous biomanufacturing is expected to double in the next 5 years, garnering larger share from conventional batch processing.
Alternative and Novel downstream bioprocessing techniques generate a significant share of over $16 billion growth overall.
Increasing demand for major end products led by monoclonal antibodies, vaccines, biosimilars, bio betters, plasma therapy, cell & gene therapy, and human microbiome therapeutics, are growing at 3 times the rate of conventional therapeutics.
Top 10 disruptions in Biopharma Manufacturing
90 minutes of brainstorming among 4 great minds which will aim at bringing out a tangible action plan by discussing the question given below:
Vice President of Growth, MarketsandMarkets
Vice President (Healthcare Research), MarketsandMarkets
President & CEO, PDC*line Pharma
CMC consultant, Cell Gene Therapy
Senior Director of Sales and Marketing, Packaging Compliance Labs
Ph.D.- Biotech (IIT-R) CEO & Director - Biologics & Licensing, Paras Biopharmaceuticals